Apogee Therapeutics, Inc.
APGE
Ранг среди акций
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Цена акции
$135.07
Последняя синхронизация: 2026-09-04
Рыночная капитализация
$8.36B
Изменение (1 день)
0.00%
Изменение (1 год)
144.91%
Страна
US
Торговля Apogee Therapeutics, Inc. (APGE)
Категория
Healthcare
EPS для Apogee Therapeutics, Inc. (APGE)
EPS по состоянию на June 2026 TTM: $-4.34
Согласно последним финансовым отчетам и цене акций Apogee Therapeutics, Inc., текущий EPS компании (TTM) составляет $-4.34. В конце 2023 EPS компании составлял $-1.66, больше, чем показателю 2022 года, равному $-0.79.
История EPS компании Apogee Therapeutics, Inc. с 2022 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
